Effects of sex steroids on skin 5α-reductase activity in vitro

Obstetrics and Gynecology

Volumn 78, Issue 1, 1991, Pages 103-107

  Cassidenti, Denise L ^a   Paulson, Richard J ^a   Serafini, Paulo ^a   Stanczyk, Frank Z ^a   Lobo, Rogerio A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PROGESTERONE; SEX HORMONE; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENITAL SKIN; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

ADULT; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; HUMAN; IN VITRO; LEVONORGESTREL; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGE; NORETHINDRONE; NORGESTREL; PROGESTERONE; SKIN; STEROIDS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0025869465     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Serafini P, Ablan F, Lobo RA. 5α-reductase activity in the genital skin of hirsute women. J Clin Endocrinol Metab 1985;60:349–55.
2. Serafini P, Lobo RA. Increased 5α-reductase activity in idiopathic hirsutism. Fertil Steril 1985;43:74–8.
3. Mowszowicz I, Melanitou E, Doukani A, Wright F, Kuttenn F, Mauvais-Jarvis P. Androgen binding capacity and 5α-reductase activity in pubic skin fibroblasts from hirsute patients. J Clin Endocrinol Metab 1983;56:1209–13.
4. Lobo RA, Goebelsmann U, Horton R. Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 1983;57:393–7.
5. Mauvais-Jarvis P, Kuttenn F, Baudot N. Inhibition of testosterone conversion to dihydrotestosterone in men treated percutaneously by progesterone. J Clin Endocrinol Metab 1974;38:142–7.
6. Serafini PC, Catalino J, Lobo RA. The effect of spironolactone on genital skin 5α-reductase activity. J Steroid Biochem 1985;23:191–4.
7. Kuttenn F, Rigaud C, Wright F, Mauvais-Jarvis P. Treatment of hirsutism by oral cyproterone acetate and percutaneous oestradiol. J Clin Endocrinol Metab 1980;51:1107–11.
8. Eil C, Edelson SK. The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J Clin Endocrinol Metab 1984;59:51–5.
9. Mauvais-Jarvis P, Kuttenn F, Lecomte P, Mandelbaum J. Implication du systeme hypothalamo-hypophysaire dans le syndrome des ovaires polykystiques. In: Scholler R, ed. Exploration de l’unite hypothalamo-hypophysaire. Paris: Sepe, 1977:467.
10. Dean HJ, Winter JSD. The effect of five synthetic progestational compounds on 5α-reductase activity in genital skin fibroblast monolayers. Steroids 1984;43:13–23.
11. Brooks JR. Treatment of hirsutism with 5α-reductase inhibitors. Clin Endocrinol Metab 1986;15:391–405.
12. Gordon GG, Southren AL, Tochimoto S, et al. Effect of medroxyprogesterone acetate (Provera) on the metabolism and biological activity of testosterone. J Clin Endocrinol Metab 1970;30:449–56.
13. Wilson JD, Walker JD. The conversion of testosterone to 5α- androstan-17β-ol-3-one (dihydrotestosterone) by skin slices in man. J Clin Invest 1969;48:371–9.
14. Mauvais-Jarvis P. Regulation of androgen receptor and 5α-reductase in skin of normal and hirsute women. Clin Endocrinol Metab 1986;15:307–17.
15. Rosenfield RL, Maudelonde T, Moll GW Jr. Biologic effects of hyperandrogenemia in polycystic ovary syndrome. Semin Reprod Endocrinol 1984;2:281–96.
16. Kuttenn F, Mauvais-Jarvis P. Testosterone 5α-reduction in the skin of normal subjects and of patients with abnormal sex development. Acta Endocrinol 1975;70:164–76.
17. Voigt W, Fernandez EP, Hsia SL. Transformation of testosterone into 17β-hydroxy-5α -androstan-3-one by microsomal preparations in human skin. J Biol Chem 1970;245:5594–9.
18. Liao S. Molecular actions of androgens. In: Litwack G, ed. Biochemical actions of hormones. Vol IV. New York: Academic Press, 1977:351–405.
19. Givens JR, Andersen RN, Wiser L, Fish SA. Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive. J Clin Endocrinol Metab 1974;38:727–35.